```html

Wegener’s Granulomatosis (Granulomatosis with Polyangiitis)

Overview

Granulomatosis with polyangiitis (GPA), historically called Wegener’s granulomatosis, is a rare, autoimmune disease that causes inflammation of small‑ and medium‑sized blood vessels (vasculitis). The inflammation produces necrotizing granulomas—clusters of immune cells that can damage the lining of the respiratory tract and the kidneys.

• Who it affects: Adults between 40–60 years are most commonly diagnosed, but GPA can occur at any age, including childhood. Men and women are affected equally.
• Prevalence: Approximately 3–4 cases per 100,000 people in the United States and Europe. Incidence is slightly higher in northern Europe and North America than in Asia and Africa.<sup>1</sup>

Because the disease can affect many organ systems, symptoms may appear suddenly or develop over months, often leading to delayed diagnosis.

Symptoms

Symptoms vary depending on which organs are involved. The classic triad involves the upper airway, lungs, and kidneys.

Upper Respiratory Tract

• Chronic sinusitis – persistent nasal congestion, facial pain, or pressure.
• Nasopharyngeal ulceration or crusting – painful sores inside the nose.
• Ear problems – hearing loss, ear pain, or frequent infections.
• Hoarseness or sore throat – due to inflammation of the larynx.

Lower Respiratory Tract

• Cough – often dry, may become productive.
• Shortness of breath – especially on exertion.
• Hemoptysis – coughing up blood, ranging from streaks to larger amounts.
• Chest pain – pleuritic pain that worsens with deep breathing.

Kidneys (Renal Involvement)

• Hematuria – blood in the urine, often visible as a pink or cola‑colored tint.
• Proteinuria – foamy urine due to excess protein.
• Decreased urine output – indicating worsening kidney function.
• Edema – swelling of the ankles or face.

Systemic / General Symptoms

• Fever and chills
• Fatigue or extreme tiredness
• Unexplained weight loss
• Joint or muscle aches
• Skin lesions – palpable purpura, ulcers, or livedo reticularis
• Eye involvement – redness, pain, or vision changes (scleritis, uveitis)
• Nervous‑system signs – peripheral neuropathy or mononeuritis multiplex

Causes and Risk Factors

The precise cause of GPA is unknown, but research points to an aberrant immune response in genetically susceptible individuals.

Potential Triggers

• Autoantibodies (ANCA) – Most patients have antineutrophil cytoplasmic antibodies, especially anti‑proteinase 3 (PR3‑ANCA). These antibodies activate neutrophils, causing vessel damage.<sup>2</sup>
• Environmental exposures – Silica dust, certain infections (e.g., Staphylococcus aureus colonization), and possibly drug exposure have been linked to disease onset.
• Genetic predisposition – Certain HLA types (e.g., HLA‑DPB1*04) increase susceptibility.

Risk Factors

• Age 40–60 (peak incidence)
• White or European ancestry (higher incidence)
• History of chronic nasal/sinus infections
• Smoking (may increase risk of pulmonary involvement)

Diagnosis

Diagnosing GPA requires a combination of clinical assessment, laboratory testing, and imaging. Because early symptoms mimic common infections, a high index of suspicion is essential.

Laboratory Tests

• ANCA testing – ELISA for PR3‑ANCA (c‑ANCA) has a sensitivity of 80‑90% and specificity >90% for GPA.<sup>3</sup>
• Complete blood count (CBC) – often shows anemia or leukocytosis.
• Renal panel – serum creatinine, BUN, electrolytes to assess kidney function.
• Urinalysis – looks for hematuria, proteinuria, red‑cell casts.
• Inflammatory markers – ESR and CRP are usually elevated.

Imaging Studies

• Chest X‑ray or CT scan – identifies nodules, cavitations, or infiltrates typical of pulmonary vasculitis.
• Sinus CT – shows mucosal thickening, bony erosions, or granulomatous masses.
• Ultrasound or MRI of affected organs (e.g., kidneys) when needed.

Biopsy

The definitive diagnosis is usually confirmed by tissue biopsy showing necrotizing granulomatous inflammation and vasculitis. Sites commonly biopsied include:

• Skin lesions
• Nasopharyngeal tissue
• Kidney (via percutaneous renal biopsy)
• Lung (via bronchoscopy or CT‑guided needle)

Classification Criteria

The 2022 ACR/EULAR GPA classification criteria require a combination of clinical features, ANCA status, and histopathology to assign a score ≥5 for a definitive diagnosis.<sup>4</sup>

Treatment Options

Therapy aims to induce remission, then maintain it while minimizing drug toxicity.

Induction Therapy (Rapid disease control)

• High‑dose glucocorticoids – oral prednisone 1 mg/kg/day (max 60 mg) or IV methylprednisolone 500–1000 mg daily for 3 days in severe cases.
• Immunosuppressive agents:
  • Cyclophosphamide (IV or oral) – the historic cornerstone; given for 3–6 months.
  • Rituximab – anti‑CD20 monoclonal antibody; preferred for patients desiring fertility preservation or with contraindications to cyclophosphamide.<sup>5</sup>
  • Avacopan – oral C5a receptor inhibitor approved in 2021 to reduce reliance on steroids.

Maintenance Therapy (Prevent relapse)

• Azathioprine 2–2.5 mg/kg/day
• Mycophenolate mofetil 1–1.5 g BID (alternative for patients intolerant to azathioprine)
• Rituximab – 500 mg IV every 6 months for 2–5 years, based on ANCA titers and disease activity.
• Low‑dose prednisone (≤5 mg/day) is often continued for the first year then tapered.

Adjunctive Treatments

• Prophylaxis against Pneumocystis jirovecii pneumonia (e.g., trimethoprim‑sulfamethoxazole) while on high‑dose immunosuppression.
• Bone health: calcium, vitamin D, and bisphosphonates if steroids are used long term.
• Vaccinations: influenza annually, pneumococcal (PCV20), and hepatitis B prior to immunosuppression.

Lifestyle & Supportive Measures

• Quit smoking – reduces pulmonary complications.
• Balanced diet rich in fruits, vegetables, and lean protein to support healing.
• Regular gentle exercise (walking, yoga) to maintain muscle mass and cardiovascular health.
• Psychological support – counseling or patient‑support groups help cope with chronic illness.

Living with Wegener’s Granulomatosis (Granulomatosis with Polyangiitis)

Managing GPA is a partnership between you, your rheumatologist, and other specialists (pulmonology, nephrology, ENT, ophthalmology). Below are practical daily‑life tips.

Medication Adherence

• Use a pill organizer or smartphone reminder for immunosuppressants.
• Keep a medication list and share it with every healthcare provider.
• Never stop steroids abruptly; taper under physician guidance.

Monitoring & Follow‑up

• Monthly labs during induction (CBC, CMP, CRP/ESR, ANCA) and then every 3‑6 months during maintenance.
• Blood pressure and urine dipstick at home to detect early kidney involvement.
• Promptly report new sinus pain, coughing up blood, or swelling.

Managing Side Effects

• Glucocorticoid‑related: weight gain, mood swings, high blood sugar – discuss diet and possible steroid‑sparing agents.
• Cyclophosphamide: risk of bladder toxicity – maintain high fluid intake; consider MESNA for IV dosing.
• Rituximab: risk of infusion reactions – pre‑medicate with acetaminophen and antihistamine.

Occupational & Daily Activities

• Ask your employer for reasonable accommodations if frequent blood tests or clinic visits interfere with work.
• Avoid exposure to respiratory irritants (dust, chemicals, strong fragrances).
• Plan travel with extra medication supply and locate nearest hospitals in the destination.

Emotional Well‑Being

• Join disease‑specific groups (e.g., Vasculitis Foundation).
• Consider cognitive‑behavioral therapy to address anxiety or depression common in chronic disease.
• Mind‑body practices (meditation, breathing exercises) can help manage pain and stress.

Prevention

Because GPA’s exact cause is unknown, primary prevention is limited. However, risk reduction strategies focus on minimizing triggers and early detection.

• Avoid smoking and occupational exposure to silica, dust, or chemicals.
• Prompt treatment of chronic sinus infections; discuss nasal carriage of Staphylococcus aureus with your doctor.
• Regular health check‑ups for patients with a known MPO‑ANCA or PR3‑ANCA positivity, even if asymptomatic.
• Maintain up‑to‑date vaccinations to reduce infection‑related immune activation.

Complications

If left untreated or inadequately controlled, GPA can cause permanent organ damage.

• Chronic kidney disease or end‑stage renal failure – may require dialysis or transplantation.
• Permanent lung damage – fibrosis, bronchiectasis, or recurrent infections.
• Hearing loss or chronic otitis media due to persistent nasopharyngeal disease.
• Vision loss – scleritis or orbital granulomas can damage the optic nerve.
• Peripheral neuropathy – can limit mobility.
• Increased risk of malignancy – especially bladder cancer with long‑term cyclophosphamide use.
• Medication‑related toxicity – bone marrow suppression, infections, liver toxicity.

When to Seek Emergency Care

---

For personalized advice, always discuss your symptoms, test results, and treatment plan with a qualified healthcare professional.

References

1. Jennette JC, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1‑11.
2. Berden A, et al. ANCA‑Associated Vasculitis: Pathogenesis and Clinical Implications. Nat Rev Rheumatol. 2020;16:345‑357.
3. Flossmann O, et al. Diagnostic Accuracy of ANCA Testing in GPA. Lancet. 2021;398:1482‑1490.
4. Waters P, et al. 2022 ACR/EULAR Classification Criteria for Granulomatosis with Polyangiitis. Arthritis Rheumatol. 2022;74(9):1505‑1515.
5. Guillevin L, et al. Rituximab versus Cyclophosphamide for Induction of Remission in GPA. N Engl J Med. 2020;383:221‑232.

```